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An estimated 34 million people are HIV-infected globally; South 
Africa (SA) carries the highest burden with an estimated 5.6 million 
people infected.1 A major scale-up of public sector antiretroviral 
therapy (ART) has seen 1.4 million people start ART,2 and an 
increasing proportion of eligible individuals initiating treatment.3 
Tuberculosis (TB) case notifications per annum in SA reached 
396 554 in 2010, with 61% of incident TB cases HIV co-infected.4 
TB prevalence is high at initiation of ART: 2 clinics in Cape Town 
reported concomitant TB treatment (TBT) in 25% and 40% of 
patients, respectively, at time of ART initiation.5,6 In SA, 42% of HIV-
positive TB cases received both ART and TBT in 2009, compared 
with 18% in 2008.3
Drug-induced liver injury (DILI) is a well-recognised complication 
of TBT and ART. DILI is frequently encountered at healthcare 
facilities in SA and is especially challenging to manage in TB/HIV 
co-infected patients. Hepatotoxicity complicates TBT in 5 - 33% 
of patients.7 Studies reporting high rates include patients with 
subclinical elevations of liver enzymes. Depending on the regimen, 
hepatotoxicity develops in 9 - 30% of patients receiving ART.8 HIV 
infection itself is associated with an increased risk of major TBT 
side-effects.9 Liver dysfunction due to TBT or ART carries numerous 
risks, including: (i) direct morbidity and mortality due to liver failure, 
(ii) disease progression due to interruption of optimal therapy, (iii) 
complications of prolonged hospitalisation, and (iv) TBT or ART 
resistance related to interruptions.10 
G F Jooste Hospital (GFJH), a secondary-level referral hospital 
in Cape Town, serves communities with a high burden of TB/HIV 
co-infection. There has been a major scale-up of treatment services 
for both infections in the hospital’s catchment area in recent years. 
Patients from surrounding primary care HIV and TB clinics with 
adverse reactions to treatment of either disease, including significant 
symptoms or signs of liver injury, are referred for management to 
GFJH.
We aimed to assess the proportion of significant liver dysfunction 
caused by TBT and/or ART among patients with liver dysfunction 
presenting to a secondary hospital (GFJH), and to describe management 
and outcomes.
Methods
A retrospective observational study was conducted and results of all 
liver function tests (LFTs) performed at the GFJH National Health 
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Background. G F Jooste Hospital (GFJH) is a secondary-level referral 
hospital in a high HIV and tuberculosis (TB) co-infection setting. 
Aims. To assess the proportion of significant drug-induced 
liver injury (DILI) due to tuberculosis treatment (TBT) and/or 
antiretroviral therapy (ART) among patients presenting with liver 
dysfunction at GFJH and to describe management and outcomes. 
Methods. A retrospective observational study was performed of 
all cases referred to GFJH with significant liver dysfunction from 1 
January to 30 June 2009. Significant liver dysfunction was defined 
by alanine transaminase (ALT)≥200 U/l or total bilirubin (TBR)≥44 
µmol/l. TBT- or ART-associated DILI was defined as significant 
liver dysfunction attributed to TBT and/or ART and which resulted 
in the halting of treatment or the adjustment thereof. Outcome 
measures included case numbers, descriptive data, and in-hospital 
and 3-month mortality.
Results. A total of 318/354 cases of significant liver dysfunction 
were reviewed: 71 were classified as TBT- or ART-associated 
DILI, while liver dysfunction was attributed to other causes in 
the remainder. In-hospital and 3-month mortality of TBT- or 
ART-associated DILI patients was 27% (n=19) and 35% (n=25), 
respectively. The majority of deaths were related to sepsis or sepsis 
complicating liver dysfunction. Twenty-three patients (32%) were 
lost to follow-up; 23 (32%) were alive and in outpatient care 3 
months after presentation.
Conclusions. TBT- or ART-associated DILI is a common reason 
for presentation at a referral hospital in South Africa. In-hospital 
and 3-month mortality are high. Prospective studies are needed to 
define optimal management. 
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Laboratory Service laboratory from 1 January to 30 June 2009 were 
reviewed. Hepatocellular injury is characterised by a marked rise 
in serum transaminases, aspartate aminotransferase (AST) and 
alanine transaminase (ALT). Cholestatic liver injury is characterised 
by a rise in alkaline phosphatase, gamma-glutamyltransferase and/
or raised total bilirubin (TBR).11 Significant hepatocellular injury 
and cholestatic injury was defined as resulting in a Grade 3 or 4 
elevation of ALT≥200 U/l (>5 times the normal upper limit) and 
TBR≥44 µmol/l (>2.5 times the normal upper limit), respectively.12 
Patients who fulfilled one or both criteria were included. Sepsis was 
documented when clinical presentation was compatible and the 
admitting team managed infection as the primary cause of illness. 
Hepatic encephalopathy was documented by the admitting team. 
Patient records were reviewed and data recorded on a standardised 
form. DILI was attributed to TBT or ART if either regimen was 
interrupted or adjusted. Cases not classified as TBT- or ART-
associated DILI were classified as ‘liver dysfunction due to other 
causes’. This included: (i) patients receiving TBT and ART and 
diagnosed with hepatic TB-associated immune reconstitution 
inflammatory syndrome (TB-IRIS), (ii) patients presenting with 
untreated disseminated TB, (iii) patients receiving TBT and/or 
ART and presenting with liver injury with no subsequent change 
or discontinuation of TBT or ART, and (iv) patients diagnosed with 
alternative causes of liver dysfunction.
The University of Cape Town Human Research Ethics Committee 
approved the study (HREC ref: 522/2009). Statistical analyses were 
conducted with STATA 11.1 software (2009).
Management 
Patients receiving TBT and ART were managed at primary care 
clinics according to national treatment guidelines.13,14 Patients with 
significant symptoms or signs suggestive of DILI were referred to 
GFJH. Patients were admitted or managed as outpatients depending 
on clinical severity and LFT results. GFJH has an infectious diseases 
referral clinic with capacity to manage stable DILI patients as 
outpatients.
In patients with TBT-associated DILI, a decision was made to cease 
treatment temporarily or to switch to alternative and less hepatotoxic 
treatment. Cessation of TBT was defined as discontinuation of all 
TBT for longer than a day. In patients whose treatment had been 
interrupted, a less hepatotoxic regimen, typically consisting of 
streptomycin, ethambutol and ofloxacin, was usually commenced 
once LFT results improved. Rifampicin and isoniazid was then 
‘re-challenged’ in a stepwise manner after LFT results normalised. 
Rifampicin or isoniazid was started at a low dose and increased to 
full dose over a few days with concurrent monitoring of ALT. This 
was followed by similar introduction of the second drug. Once full-
dose rifampicin and isoniazid were re-introduced, certain of the less 
hepatotoxic drugs were discontinued. Optimal TBT was defined as 
rifampicin-based therapy.
Depending on the suspected cause and severity of ART-associated 
DILI, generally either: (i) ART was ceased, (ii) a single drug substitution 
was made, or (iii) more hepatotoxic ART (e.g. nevirapine) was interrupted 
and replaced within a few days (e.g. by efavirenz 5 - 7 days later), while 
less hepatotoxic ART (e.g. stavudine and lamivudine) was continued. 
Optimal ART was defined as triple ART medication from at least 2 
classes.
Outcome assessment
Clinical management and outcome data were ascertained by review 
of patient records. In-hospital and 3-month (within 90 days of 
presentation) mortality were recorded, including the cause of death 
where possible. Only in-hospital mortality was recorded for patients 
with liver injury due to other causes. Three-month retention in 
care was also recorded. In the case of TBT and/or ART-associated 
DILI, the Clinicom and eKapa electronic databases were consulted 
to ascertain follow-up and mortality documented elsewhere in the 
Western Cape. Loss to follow-up was defined as inability to trace any 
patient data after discharge, within 3 months of presentation.
Results
A total of 354 patients met the criteria for inclusion; 36 (10.2%) 
were excluded due to incomplete or missing records. Of 318 cases 
reviewed, 71 were classified as TBT- and/or ART-associated DILI. 
In 247 cases, liver injury was attributed to other causes (Fig. 1). 
Among many other causes of liver injury, the most common was 
sepsis-induced liver dysfunction, evident from clinical presentation 
and LFT results; 27 patients receiving TBT or ART were not 
diagnosed with TBT- or ART-associated DILI because no alteration 
was made to TBT or ART. 
Baseline characteristics
Of the 318 patients, 47% were women and 41% were HIV-infected 
(Table 1). At presentation, 18% were receiving ART, 26% were 
receiving TBT and 10% were receiving concomitant TBT and ART. 
ART regimens included: (i) stavudine (or zidovudine), lamivudine 
and efavirenz (n=17; 53%); (ii) stavudine (or zidovudine), lamivudine 
and nevirapine (n=9; 28%); and (iii) protease inhibitor (PI)-based 
ART (n=4; 13%). Three patients receiving TBT were treated with 
Fig. 1. Hepatitis or cholestasis: description of the cohort. TB = tuberculosis; 
TBT = TB treatment; ART = antiretroviral therapy; DILI = drug-induced 
liver injury.
*Twenty-seven (10%) patients in this group were also receiving TBT or ART, but patients 
presented with a syndrome suggestive of sepsis and were treated for sepsis with no 
adjustment to TBT or ART. 
†Patients presented with jaundice and diagnosis of disseminated TB was made during 
admission, i.e. patients were not receiving TBT or ART at presentation with liver 
dysfunction. Cause of jaundice was attributed to TB infiltration of the liver. 
‡Including gastro-intestinal tract malignancies, other malignancies with liver metastases, 
TB-associated immune reconstitution inflammatory syndrome, toxins, cardiac causes 
with liver congestion, unknown causes (not receiving TBT or ART) and a group of 
miscellaneous causes (including leptospirosis; echinococcus; amoebiasis; cryptococcosis)
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PI-based ART and thus double-dose lopinavir/ritonavir. In the 
TBT- or ART-associated DILI category, a history of cotrimoxazole 
prophylaxis was available in 48/60 (80%) of the HIV-seropositive 
patients, and of these, 28 (47%) were receiving cotrimoxazole 
at presentation. Fifty-seven (80%) patients in this category were 
screened for hepatitis B surface antigen; 8 (14%) were positive. 
Clinical presentation and management 
Median length of hospital stay was 13 days (interquartile range (IQR) 
7 - 20) in the 87% of TBT- or ART-associated DILI patients who were 
admitted. Patients presented as follows: 56 (79%) with cholestasis 
(TBR≥44 µmol/l), 31 (44%) with hepatocellular injury (ALT≥200 U/l) 
and 18 (25%) with both. Fifteen (21%) had hepatic encephalopathy 
(Table 2). One or more possible alternate causes of liver dysfunction, 
including sepsis and TB-IRIS, were documented in 53 (75%) of 
patients. 
TBT was ceased in 29 (49%) patients, with a median of 16.5 (IQR 
14 - 26) days off optimal treatment. Less hepatotoxic TBT was initiated 
in 38 (64%) patients prior to re-challenge with rifampicin/isoniazid. 
Change in ART was individualised and varied widely. 
Optimal rifampicin-based TBT was not re-introduced in 27/59 
(45.8%) patients who presented while receiving TBT, for the following 
reasons: (i) death (n=14), (ii) transfer to another facility without 
particulars of subsequent re-challenge (n=5), (iii) absence of evidence 
for initial TB diagnosis (n=4), (iv) discharge with less hepatotoxic TBT 
and intention to re-challenge at a later stage (n=2), (v) presentation of 
DILI while receiving less hepatotoxic TBT which was continued while 
ART was adjusted (i.e. managed as ART-associated DILI) (n=1), (vi) 
completion of TBT (n=1), or (vii) patient absconded (n=1).
ART was interrupted in 11 patients (34%) and altered in 23 (74%). 
Patients spent a median of 25 (IQR 7 - 40) days off optimal ART 
(triple therapy). In 27 (38%) TBT- or ART-associated DILI patients, 
additional investigations were performed, including abdominal 
ultrasound (n=24), computed tomography (CT) of the abdomen 
(n=2), and liver biopsy (n=1; performed during DILI relapse). 
Patients who were discharged and followed up as outpatients 
(n=21, 29.6%) had a median of 4.5 visits in the 3 months following 
presentation. Seven (9.9%) patients had subsequent relapse of hepatitis 
Table 1. Baseline characteristics of patients who presented with cholestasis or hepatitis
Total (N=318) TB or ART* (n=71) Other (n=247)
Age (years), median (IQR) 39 (30 - 50) 39 (30 - 43) 39 (29 - 54)
Sex: female, n (%) 165 (51.9) 44 (62) 121 (49)
HIV Status
Tested for HIV, n (%) 190 (59.7) 69 (97.2) 121 (49)
HIV-positive, n (%) 144 (45.3) 60 (84.5) 84 (34)
HIV-negative, n (%) 46 (14.5) 9 (12.7) 37 (15)
CD4 count, median (IQR) 59 (26 - 179) 75 (28 - 189) 57 (26 - 174)
Tested for hepatitis B surface antigen,§ n (%) - 57 (80.3) -
Positive, n (%) - 8 (11.3) -
Receiving ART at presentation,¶ n (%) 63 (19.8) 32 (45.1) 31 (12.6)
Days of ART, median (IQR) 60 (30 - 251) 41 (29 - 81) 105 (38 - 565)
Receiving TBT at presentation, n (%) 92 (28.9) 59 (83.1) 33 (13.4)
Days of TBT, median (IQR) 56 (20 - 129) 40 (15 - 89)|| 99 (32.5 - 158.5)
Regimen I TBT,† n (%) 62 (19.5) 44 (62)** 18 (54.6)
Regimen II TBT,‡ n (%) 25 (7.8) 12 (17) 13 (39.4)
Concomitant TBT and ART, n (%) 36 (11.3) 20 (28.2) 16 (6.5)
Cotrimoxazole prophylaxis documented,†† n (%) 127 (39.9) 48 (67.6) 79 (32)
Receiving cotrimoxazole, n (%) 59 (18.6) 28 (39.4) 31 (12.6)
*Patients with TBT- and/or ART-associated DILI. 
†Regimen I TBT: 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol, followed by 4 months of rifampicin and isoniazid.
‡Regimen II TBT: 2 months of rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin, followed by 1 month of rifampicin, isoniazid, pyrazinamide and ethambutol, followed by 5 
months of rifampicin, isoniazid and ethambutol.
§Data were only captured for TBT- or ART-associated DILI.
¶TBT- or ART-associated DILI: 11 known HIV-infected patients with no available information about ART use. Other causes: 1 known HIV-infected patient with no available information about ART use. 
||
8 patients with TBT- or ART-associated DILI: unknown duration of TBT.
**
11 patients with TBT- or ART-associated DILI: unknown TB regimen.
††
Cotrimoxazole prophylaxis documented in known HIV-infected patients. 
Fig. 2. Cause of in-patient death in TBT- or ART-associated DILI.
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Table 2. Clinical presentation and management of TBT- or ART-associated DILI patients
TBT- or ART-associated DILI (N=71)
Admitted to hospital, n (%) 62 (87.3)
Days in hospital, median (IQR) 13 (7 - 20)
Laboratory results at presentation
AST (U/l), median (IQR) 245 (117 - 628)
ALT (U/l), median (IQR) 157 (71 - 353)
Patients with ALT≥200 U/l, n (%) 31 (43.6)
GGT (U/l), median (IQR) 108 (61 - 292)
ALP (U/l), median (IQR) 110 (80 - 231)
TBR (µmol/l), median (IQR) 88 (50 - 128)
Patients with TBR≥44 µmol/l, n (%) 56 (78.9)
Patients with ALT≥200 U/l and TBR≥44 µmol/l, n (%) 18 (25.4)
INR performed at presentation, n (%) 42 (59.2)
INR, median (IQR)* 1.7 (1.3 - 3)
Clinical features
Hepatic encephalopathy, n (%) 15 (21.1)
Case fatality rate,† n (%) 8 (53.3)
Differential diagnosis,‡ n (%) 53 (74.7)
Number of differential diagnoses,§ median (range) 2 (1 - 3)
Patients receiving TBT, n (%) 59 (83)
Treatment completely interrupted, n (%) 29 (49.2)
Less hepatotoxic TBT initiated, n (%) 38 (64.4)
TB medication restarted,¶ n (%) 32 (54.2)
Days off optimal TBT,|| median (IQR) 16.5 (14 - 26)
Patients receiving ART, n (%) 32 (45)
Treatment completely interrupted, n (%) 11 (34.4)
Any change made to ART,** n (%) 23 (71.9)
Days off optimal ART,†† median (IQR) 25 (7 - 40)
Additional investigations performed, n (%) 27 (38)
USS abdomen 24 (33.8)
CT abdomen 2 (2.8)
Liver biopsy‡‡ 1 (1.4)
Outpatient follow-up visits,§§ median (IQR) 4.5 (3 - 7)
Relapse of hepatitis or cholestasis, n (%) 7 (9.9)
Admitted to hospital, n (%) 5 (7)
Days in hospital, median (IQR) 12 (12 - 21)
Outpatient follow-up visits following relapse,§§ median (IQR) 6 (5 - 8)
AST = aspartate aminotransferase; ALT = alanine transaminase; GGT = gamma-glutamyltransferase; ALP = alkaline phosphatase; TBR = total bilirubin; INR = international normalised ratio.
*Five (7.35%) patients had other reason contributing to high INR: warfarin therapy (n=2) and congestive cardiac failure (n=3). 
†Case fatality rate in patients who presented with hepatic encephalopathy.
‡Patients who had significant differential diagnoses at time of DILI.
§Significant differential diagnoses per patient.
¶Rifampicin and isoniazid restarted.
|| Rifampicin-based TBT.
**Including ART completely stopped.
††Triple therapy ART.
‡‡One patient had a liver biopsy at subsequent relapse of hepatitis.
§§Outpatient follow-up visits 3 months after presentation.
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or cholestasis; 5 (71.4%) were re-admitted to hospital for a median of 
12 days (IQR 12 - 21); 1 died in hospital due to sepsis and 6 were alive 
and in care 3 months after presentation of relapse. 
Patient outcomes 
The Kaplan-Meier survival estimate is shown in Fig. 3. In-hospital 
mortality of the cohort was 27% (n=19) and 53% in patients who 
presented with hepatic encephalopathy. Common causes of death 
during initial admission included sepsis, a combination of sepsis and 
active TB or DILI, and liver failure (Fig. 2). Three of 19 in-hospital deaths 
occurred after completion of TBT re-challenge; causes were sepsis (2) 
and unknown (1, unexpected death after initial improvement). At 3 
months after presentation, 25 (35%) patients had died, 23 (32%) were 
alive and in care, and 23 (32%) were lost to follow-up (Table 3). 
In cases of ‘liver dysfunction due to other causes’, 71 (28.7%) 
patients died during admission. This included 34 patients admitted 
with sepsis, of whom 14 were receiving TBT or ART.
Discussion
To our knowledge, this is the first study describing the management, 
outcome and high burden of TBT- or ART-associated DILI at a referral 
hospital in a high TB/HIV prevalence community. Over 6 months there 
were 71 cases. This may reflect under-ascertainment, accepting that – 
in the absence of a confirmatory test for DILI – some patients admitted 
with TBT- or ART-associated DILI would have been misclassified as 
having other causes of liver dysfunction such as TB-IRIS or sepsis. 
TBT was a frequent cause of DILI in our study. TBT-attributed DILI 
may reduce TBT effectiveness due to a negative effect on adherence, 
treatment interruption and substitution with less effective TB medication. 
TBT-associated DILI may be fatal if not recognised and managed early.10 
We attributed DILI to ART in 23/32 patients receiving such 
therapy. Medication of both first- and second-line ART regimens 
may cause DILI. Nucleoside reverse transcriptase inhibitors 
(NRTIs) may cause fatty liver related to mitochondrial toxicity. 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) cause 
liver injury related to immune-mediated hypersensitivity. The 
mechanism of PI-induced DILI is not entirely understood.8 In 
patients receiving lopinavir/ritonavir, additional ritonavir or 
double-dose lopinavir/ritonavir is required to counteract rifampicin 
induction, and high incidence of hepatotoxicity has been reported 
in such patients.15,16 Three patients were receiving lopinavir/
ritonavir-based ART and TBT; 2 were alive and in care 3 months 
after presentation and 1 was lost to follow-up.
Twenty patients were on concomitant rifampicin-based TBT and 
ART, which have overlapping toxicities. The cause of liver dysfunction 
in these patients is likely multi-factorial. The pathogenic mechanisms 
of DILI are complex, unpredictable and related to medication 
and genetic factors.11,17 Management is complex and needs to be 
individualised. TBT or ART was ceased or altered in all 20 cases, 
leading to prolonged hospital admission for drug re-challenge and 
increased vulnerability to disease progression and other infections. 
There are considerable risks associated with prolonged hospital stay 
in the context of advanced HIV infection, particularly nosocomial 
sepsis.18 We observed more cases of DILI related to TBT alone (n=39) 
than with ART alone (n=12) or concomitant ART and TBT (n=20), 
possibly reflecting that more patients were initiated on TBT than 
on ART in the hospital catchment area during the study period. 
Alternatively, TBT may be a more common cause of DILI.
Adding to the complexity, cotrimoxazole may also cause DILI; 
prophylactic treatment is often stopped during management of DILI, 
rendering patients vulnerable to opportunistic infections. Chronic 
hepatitis B is also an important co-factor in DILI; concomitant TBT 
significantly increases the risk of hepatotoxicity.19 Hepatitis B surface 
antigen was positive in a minority of cases in our study; 8/57 patients 
with TBT- or ART-associated DILI.
A striking finding was the high mortality associated with TBT- or 
ART-associated DILI (35% at 3 months after presentation) with a 
median time to death of 11 days (IQR 5 - 31). Mortality was likely 
under ascertained, as it is possible that some patients recorded as lost 
to follow-up really died. In comparison, mortality in a general cohort 
of patients with HIV-associated TB in our setting was only 8% during 
6 months of TBT.20 
In our study, the most common cause of death ascertained was 
sepsis, highlighting the vulnerability of patients with liver injury to 
bacterial and other infections. Close monitoring for community- 
and hospital-acquired bacterial infections and early diagnosis with 
appropriate antimicrobial treatment may improve outcome. Liver 
failure was the cause of death in only a minority of cases. Further 
studies are required to define reasons for the high mortality among 
DILI patients; this rate may reflect direct and indirect consequences Fig. 3. Kaplan-Meier survival estimate in TBT- or ART-associated DILI.
Table 3. Three-month outcomes of TB- or ART-associated DILI patients* (N=71)
n (%) Days,† median (IQR)
Died during initial admission§ 19 (26.8) 8 (3 - 13)
Discharged; died within 3 months of presentation 6   (8.5) 59.5 (56 - 70)
Lost to follow-up within 3 months of presentation‡ 23 (32.4) 42 (18 - 57)
Discharged, alive and in care 3 months after presentation 23 (32.4) -
*Three months or 90 days from presentation with hepatitis or cholestasis. 
†Days from presentation with hepatitis or cholestasis until death or loss to follow up.
‡Lost to follow-up: no patient record available after discharge.  
§Three patients who completed TB drug re-challenge died during admission. 
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of DILI, or that DILI complicates poor prognoses owing to other 
disease-related factors. 
We acknowledge several limitations of our study. The use of 
herbal, traditional or over-the-counter medication, all of which 
may cause liver injury, was poorly documented. A retrospective 
review has many limitations: data capture was limited to 
documentation by attending clinicians and 10% of records were 
not found for review. 
Conclusions
Liver injury due to TBT- or ART-associated DILI necessitating 
referral to hospital was common and associated with high mortality 
in our study. The cause of liver injury in HIV-TB co-infected patients 
is likely multi-factorial and is complex to manage. Prospective studies 
are urgently needed to investigate optimal management strategies 
and improve outcomes of such patients. The use of early invasive 
investigations (e.g. liver biopsy) in the diagnosis and management of 
liver injury requires investigation. 
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